Canaccord Genuity lowered shares of TiGenix – American Depositary Shares (NASDAQ:TIG) from a buy rating to a hold rating in a report released on Monday, MarketBeat Ratings reports. They currently have $42.80 price objective on the stock, down from their prior price objective of $50.00.
A number of other analysts have also recently weighed in on the stock. BidaskClub cut shares of TiGenix – American Depositary Shares from a sell rating to a strong sell rating in a research note on Saturday, December 9th. Zacks Investment Research cut shares of TiGenix – American Depositary Shares from a hold rating to a sell rating in a research note on Saturday, October 21st.
Shares of TiGenix – American Depositary Shares (TIG) traded up $0.02 during trading on Monday, hitting $40.47. 16,600 shares of the stock were exchanged, compared to its average volume of 30,886. The company has a quick ratio of 1.36, a current ratio of 1.37 and a debt-to-equity ratio of 0.10. TiGenix – American Depositary Shares has a twelve month low of $14.30 and a twelve month high of $41.00.
TiGenix – American Depositary Shares Company Profile
TiGenix NV, a biopharmaceutical company, develops and commercializes therapeutics from its proprietary technology platforms of allogeneic or donor derived stem cells. Its stem cell programs are based on proprietary validated platforms of allogeneic expanded stem cells targeting autoimmune, inflammatory, and heart diseases.
Receive News & Ratings for TiGenix - American Depositary Shares Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TiGenix - American Depositary Shares and related companies with MarketBeat.com's FREE daily email newsletter.